查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1790288

美国伴侣动物骨关节炎市场规模、份额和趋势分析报告：按产品、动物、给药途径、最终用途和细分市场预测，2025 年至 2033 年

U.S. Companion Animal Osteoarthritis Market Size, Share & Trends Analysis Report By Product (Biologics, Pharmaceuticals, Viscosupplements, Nutritional Supplements), By Animal, By Route of Administration, By End-use, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

美国伴侣动物骨关节炎市场摘要

美国伴侣动物骨关节炎市场规模预计在 2024 年为 7.7697 亿美元，预计到 2033 年将达到 41.974 亿美元，2025 年至 2033 年的复合年增长率为 22.55%。预计推动市场发展的关键因素包括骨关节炎盛行率上升、研发倡议增加、新治疗方法出现以及宣传宣传活动增加。

在科技创新的推动下，美国伴侣动物骨关节炎（CA OA）市场正经历强劲成长。

提高临床意识，扩大多样化治疗方案的可近性。先进的治疗方法

预防性照护措施与饲主主导的结合正在重塑宠物（尤其是犬类）骨关节炎的治疗方式。其中最有前景的进展之一是基因疗法的进步。

ElenaVet 等基因疗法的进展已证明，在减轻骨关节炎犬疼痛和改善其活动能力方面，成功率高达 90%。这项治疗方法凸显了向缓解疾病疗法的转变，与传统的疼痛管理疗法相比，这些疗法具有长期益处。

同时，正如《DVM360》所报导的那样，由兽医主导的宣传活动透过强调早期发现、活动筛检和积极的骨关节炎管理，正在提高护理标准。这种临床关注度的提高，使饲主，并能够及时开始治疗，从而扩大了整体市场。

与这些努力相辅相成的是，专门针对犬骨关节炎（OA）配製的营养补充品日益增加。最近在美国推出的一款新型补充剂 (DVM360) 为早期和辅助治疗管理提供了处方笺选择，特别适合注重成本或寻求整体解决方案的饲主饲主。

同时，干细胞疗法等再生疗法在专科诊所和尖端诊所中日益受到青睐。正如 Fitzpatrick Referrals 所述，这些治疗方法是微创解决方案，专注于关节修復而非症状抑制，这与人们对长期修復治疗日益增长的期望相吻合。

进一步增强市场竞争力的是目前正在临床开发中的口服治疗药物，包括Can-Fite和Vetbiolix的Piclidenoson。这款A3Adenosine受体促效剂旨在提供一种便捷、非侵入性的治疗方案，预计2034年全球销售额将达到峰值，超过4.45亿美元。该药物的进展反映了投资者和临床医生对口服骨关节炎治疗作为注射药物和非类固醇消炎剂的可行替代方案的强烈信心。

总而言之，美国伴侣动物骨关节炎市场正受到全面而多方面的变革驱动，从尖端的基因和细胞疗法，到不断提升的从业人员教育和动物主人参与度。这个多元化的生态系统正在改善患者的治疗效果，并巩固美国在伴侣动物骨关节炎治疗的全球领导地位。

目录

第一章调查方法与范围

第二章执行摘要

第三章美国伴侣动物骨关节炎市场趋势与展望

  • 市场体系展望
    • 母市场
    • 子公司市场
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
    • 市场机会分析
    • 市场问题分析
  • 伴侣动物骨关节炎市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
    • 主要国家的法规结构
    • 主要动物物种数量预估（2021-2024）
    • 管道/临床试验分析
    • COVID-19影响分析

第四章美国伴侣动物骨关节炎市场：按产品的估计和趋势分析

  • 细分仪表板
  • 美国伴侣动物骨关节炎市场：产品差异分析
  • 2021 年至 2033 年美国伴侣动物骨关节炎市场规模及趋势分析（依产品）
  • 生物製药
    • 干细胞
    • 富血小板血浆（PRP）
    • 单株抗体（mAb）
    • 其他生物製药
  • 黏稠补充剂
  • 製药
    • 类固醇
    • NSAIDs
    • 其他的
  • 营养补充品

第五章美国伴侣动物骨关节炎市场：按物种的估计和趋势分析

  • 细分仪表板
  • 美国伴侣动物骨关节炎市场：动物变异分析
  • 美国伴侣动物骨关节炎市场规模与趋势分析（按动物，2021-2033 年）
  • 狗
  • 猫
  • 马

第六章美国伴侣动物骨关节炎市场：按给药途径的估计和趋势分析

  • 细分仪表板
  • 美国伴侣动物骨关节炎市场：按给药途径进行的变化分析
  • 美国伴侣动物骨关节炎市场规模及趋势分析（依给药途径），2021-2033 年
    • 口服
    • 注射
    • 肌肉注射
    • 关节内
    • 其他注射药物
    • 其他的

第七章美国伴侣动物骨关节炎市场：按最终用途的估计和趋势分析

  • 细分仪表板
  • 美国伴侣动物骨关节炎市场：依最终用途的变化分析
  • 美国伴侣动物骨关节炎市场规模及趋势分析（依最终用途），2021-2033 年
    • 兽医院/诊所
    • 电子商务
    • 其他的

第八章 竞争态势

  • 市场参与企业分类
  • 企业市场分析/堆图分析
  • 公司简介
    • Zoetis Inc.
    • Boehringer Ingelheim
    • Elanco Animal Health
    • American Regent, Inc.
    • Merck Animal Health（Merck &Co. Inc）
    • Vetoquinol SA
    • Ceva Sante Animale
    • Virbac
    • Biogenesis Bago
    • Ardent Animal Health, LLC
    • PetVivo Holdings, Inc.（Spryng）
    • Vet Stem Inc.
    • Enso Discoveries
    • Contura Vet US
    • T-Cyte Therapeutics
    • Medrego LLC.
  • 战略地图
  • 主要企业名单
Product Code: GVR-4-68040-669-7

U.S. Companion Animal Osteoarthritis Market Summary

The U.S. companion animal osteoarthritis market size was estimated at USD 776.97 million in 2024 and is projected to reach USD 4,197.40 million by 2033, growing at a CAGR of 22.55% from 2025 to 2033. Key factors expected to drive the market include the rising prevalence of osteoarthritis, increasing R&D initiative, emerging novel treatments, and increasing awareness campaigns.

The U.S. companion animal osteoarthritis (CA OA) market is undergoing robust growth, fueled by innovation,

increased clinical awareness, and broader access to diverse treatment options. A convergence of advanced therapies,

preventive care initiatives, and owner-driven demand is reshaping how OA is managed in pets, particularly dogs. One of the most promising developments is the advancement of gene therapy, exemplified by CureLab Veterinary's

ElenaVet, which demonstrated a remarkable 90% success rate in reducing pain and improving mobility in dogs with OA. This breakthrough highlights a shift toward disease-modifying approaches that offer longer-term benefits compared to conventional pain management therapies.

At the same time, veterinary-led awareness campaigns-as reported by DVM360-are raising the standard of care by emphasizing early detection, mobility screening, and proactive OA management. This growing clinical emphasis has led to better-informed pet owners and more timely treatment initiation, expanding the overall addressable market.

Complementing these efforts is the increasing availability of nutritional supplements specifically formulated for canine OA. The recent U.S. launch of a new supplement (DVM360) provides a non-prescription option for managing early-stage or adjunctive care, especially for cost-conscious pet owners or those seeking holistic solutions.

In parallel, regenerative therapies, such as stem cell treatments, are gaining momentum in specialty practices and progressive clinics. As outlined by Fitzpatrick Referrals, these therapies offer minimally invasive solutions that focus on joint restoration rather than symptom suppression-aligning with rising expectations for long-lasting, restorative care.

Further strengthening the market is a growing pipeline of oral therapeutics, including Can-Fite and Vetbiolix's Piclidenoson, currently in advanced clinical development. This A3 adenosine receptor agonist is positioned to offer a convenient, non-invasive treatment option with global peak sales projected to exceed $445 million by 2034. Its progress reflects strong investor and clinical confidence in oral OA therapies as viable alternatives to injectables and NSAIDs.

In conclusion, the U.S. CA OA market is being driven by a comprehensive, multi-modal evolution-from cutting-edge gene and cell therapies to increased practitioner education and owner engagement. This diversified ecosystem improves patient outcomes and solidifies the U.S. as a global front-runner in advancing osteoarthritis care for companion animals.

U.S. Companion Animal Osteoarthritis Market Report Segmentation

This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. companion animal osteoarthritis market report based on product, animal, route of administration, and end use:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Biologics
    • Stem Cells
    • Platelet-Rich Plasma (PRP)
    • Monoclonal Antibodies (mAb)
    • Other Biologics
  • Viscosupplements
  • Pharmaceuticals
    • Steroids
    • NSAIDS
    • Others
  • Nutritional Supplements
  • Animal Outlook (Revenue, USD Million, 2021 - 2033)
  • Canine
  • Equine
  • Feline
  • Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
  • Oral
  • Injectable
    • Intra-muscular
    • Intra-articular
    • Other Injectable
  • Topical
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Veterinary Hospitals/Clinics
  • E-commerce
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's Internal Database
    • 1.3.3. Secondary Sources
    • 1.3.4. Primary Research
  • 1.4. Information/Data Analysis
  • 1.5. Market Formulation & Visualization
  • 1.6. Data Validation & Publishing
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis
    • 1.7.2. Country Market: CAGR Calculation
  • 1.8. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Companion Animal Osteoarthritis Market Variable Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market
    • 3.1.2. Ancillary Market
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising Prevalence of Osteoarthitis
      • 3.2.1.2. Increasing R&D Initiatives
      • 3.2.1.3. Emerging Novel Treatments
      • 3.2.1.4. Increasing Awareness Campaigns
      • 3.2.1.5. Advancing Diagnostic Techniques Increasing Adoption of OA Treatment
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Regulatory Hurdles
      • 3.2.2.2. Emerging Adverse Drug Reactions (ADR)
      • 3.2.2.3. Stringent Regulations
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenge Analysis
  • 3.3. Companion Animal Osteoarthritis Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitution
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political & Legal landscape
      • 3.3.2.2. Economic and Social landscape
      • 3.3.2.3. Technological landscape
      • 3.3.2.4. Environmental landscape
    • 3.3.3. Regulatory Framework by Key Countries
    • 3.3.4. Estimated Animal Population, by Key Species, 2021 - 2024
    • 3.3.5. Pipeline/ Clinical Trials Analysis
    • 3.3.6. COVID-19 Impact Analysis

Chapter 4. U.S. Companion Animal Osteoarthritis Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Companion Animal Osteoarthritis Market: Product Movement Analysis
  • 4.3. U.S. Companion Animal Osteoarthritis Market Size & Trend Analysis, by product, 2021 to 2033 (USD Million)
  • 4.4. Biologics
    • 4.4.1. Biologics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.2. Stem Cells
      • 4.4.2.1. Stem Cells Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.3. Platelet-Rich Plasma (PRP)
      • 4.4.3.1. Platelet-Rich Plasma (PRP) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.4. Monoclonal Antibodies (mAb)
      • 4.4.4.1. Monoclonal Antibodies (mAb) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.5. Other Biologics
      • 4.4.5.1. Other Biologics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Viscosupplements
    • 4.5.1. Viscosupplements Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Pharmaceuticals
    • 4.6.1. Pharmaceuticals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.6.2. Steroids
      • 4.6.2.1. Steroids Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.6.3. NSAIDs
      • 4.6.3.1. NSAIDs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.6.4. Others
      • 4.6.4.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Nutritional Supplements
      • 4.7.1.1. Nutritional Supplements Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Companion Animal Osteoarthritis Market: Animal Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Companion Animal Osteoarthritis Market: Animal Movement Analysis
  • 5.3. U.S. Companion Animal Osteoarthritis Market Size & Trend Analysis, by animal, 2021 to 2033 (USD Million)
  • 5.4. Canine
    • 5.4.1. Canine Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Feline
    • 5.5.1. Feline Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Equine
    • 5.6.1. Equine Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Companion Animal Osteoarthritis Market: By Route of Administration Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Companion Animal Osteoarthritis Market: By Route of Administration Movement Analysis
  • 6.3. U.S. Companion Animal Osteoarthritis Market Size & Trend Analysis, by route of administration, 2021 to 2033 (USD Million)
    • 6.3.1. Oral
      • 6.3.1.1. Oral Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.2. Injectables
      • 6.3.2.1. Injectables Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.3. Intra-muscular
      • 6.3.3.1. Intra-muscular Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.4. Intra-articular
      • 6.3.4.1. Intra-articular Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.5. Other Injectables
      • 6.3.5.1. Other Injectables Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.6. Others
      • 6.3.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Companion Animal Osteoarthritis Market: By End Use Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. U.S. Companion Animal Osteoarthritis Market: By End Use Movement Analysis
  • 7.3. U.S. Companion Animal Osteoarthritis Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
    • 7.3.1. Veterinary Hospitals/Clinics
      • 7.3.1.1. Veterinary Hospitals/Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.2. E-commerce
      • 7.3.2.1. E-commerce Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.3. Others
      • 7.3.3.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
  • 8.2. Company Market Position Analysis/ Heap Map Analysis
  • 8.3. Company Profiles
    • 8.3.1. Zoetis Inc.
      • 8.3.1.1. Participant's Overview
      • 8.3.1.2. Financial Performance
      • 8.3.1.3. Product Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. Boehringer Ingelheim
      • 8.3.2.1. Participant's Overview
      • 8.3.2.2. Financial Performance
      • 8.3.2.3. Product Benchmarking
      • 8.3.2.4. Strategic Initiatives
    • 8.3.3. Elanco Animal Health
      • 8.3.3.1. Participant's Overview
      • 8.3.3.2. Financial Performance
      • 8.3.3.3. Product Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. American Regent, Inc.
      • 8.3.4.1. Participant's Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Product Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. Merck Animal Health (Merck & Co. Inc)
      • 8.3.5.1. Participant's Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Product Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. Vetoquinol S.A.
      • 8.3.6.1. Participant's Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Product Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. Ceva Sante Animale
      • 8.3.7.1. Participant's Overview
      • 8.3.7.2. Financial Performance
      • 8.3.7.3. Product Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. Virbac
      • 8.3.8.1. Participant's Overview
      • 8.3.8.2. Financial Performance
      • 8.3.8.3. Product Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. Biogenesis Bago
      • 8.3.9.1. Participant's Overview
      • 8.3.9.2. Financial Performance
      • 8.3.9.3. Product Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. Ardent Animal Health, LLC
      • 8.3.10.1. Participant's Overview
      • 8.3.10.2. Financial Performance
      • 8.3.10.3. Product Benchmarking
      • 8.3.10.4. Strategic Initiatives
    • 8.3.11. PetVivo Holdings, Inc. (Spryng)
      • 8.3.11.1. Participant's Overview
      • 8.3.11.2. Financial Performance
      • 8.3.11.3. Product Benchmarking
      • 8.3.11.4. Strategic Initiatives
    • 8.3.12. Vet Stem Inc.
      • 8.3.12.1. Participant's Overview
      • 8.3.12.2. Financial Performance
      • 8.3.12.3. Product Benchmarking
      • 8.3.12.4. Strategic Initiatives
    • 8.3.13. Enso Discoveries
      • 8.3.13.1. Participant's Overview
      • 8.3.13.2. Financial Performance
      • 8.3.13.3. Product Benchmarking
      • 8.3.13.4. Strategic Initiatives
    • 8.3.14. Contura Vet US
      • 8.3.14.1. Participant's Overview
      • 8.3.14.2. Financial Performance
      • 8.3.14.3. Product Benchmarking
      • 8.3.14.4. Strategic Initiatives
    • 8.3.15. T-Cyte Therapeutics
      • 8.3.15.1. Participant's Overview
      • 8.3.15.2. Financial Performance
      • 8.3.15.3. Product Benchmarking
      • 8.3.15.4. Strategic Initiatives
    • 8.3.16. Medrego LLC.
      • 8.3.16.1. Participant's Overview
      • 8.3.16.2. Financial Performance
      • 8.3.16.3. Product Benchmarking
      • 8.3.16.4. Strategic Initiatives
  • 8.4. Strategy Mapping
      • 8.4.1.1. Mergers & Acquisitions
      • 8.4.1.2. Partnerships & Collaborations
      • 8.4.1.3. Expansion
      • 8.4.1.4. Product launch
      • 8.4.1.5. Product Approval
      • 8.4.1.6. Others
  • 8.5. List of Key Companies
      • 8.5.1.1. List of Manufacturers
      • 8.5.1.2. List of Distributors

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 U.S. Companion Animal Osteoarthritis Market, By Product, 2021 - 2033 (USD Million)
  • Table 4 U.S. Companion Animal Osteoarthritis Market, By Animal, 2021 - 2033 (USD Million)
  • Table 5 U.S. Companion Animal Osteoarthritis Market, By Route of Administration, 2021 - 2033 (USD Million)
  • Table 6 U.S. Companion Animal Osteoarthritis Market, By End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 U.S. Companion Animal Osteoarthritis Market, Market Segmentation
  • Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 11 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 12 Porter's Five Forces Analysis
  • Fig. 13 U.S. Companion Animal Osteoarthritis Market, for By Product, 2021 - 2033 (USD Million)
  • Fig. 14 U.S. Companion Animal Osteoarthritis Market, for Biologics, 2021 - 2033 (USD Million)
  • Fig. 15 U.S. Companion Animal Osteoarthritis Market, for Stem Cells, 2021 - 2033 (USD Million)
  • Fig. 16 U.S. Companion Animal Osteoarthritis Market, for Platelet-Rich Plasma (PRP), 2021 - 2033 (USD Million)
  • Fig. 17 U.S. Companion Animal Osteoarthritis Market, for Monoclonal Antibodies (mAb), 2021 - 2033 (USD Million)
  • Fig. 18 U.S. Companion Animal Osteoarthritis Market, for Other Biologics, 2021 - 2033 (USD Million)
  • Fig. 19 U.S. Companion Animal Osteoarthritis Market, for Viscosupplements, 2021 - 2033 (USD Million)
  • Fig. 20 U.S. Companion Animal Osteoarthritis Market, for Pharmaceuticals, 2021 - 2033 (USD Million)
  • Fig. 21 U.S. Companion Animal Osteoarthritis Market, for Steroids, 2021 - 2033 (USD Million)
  • Fig. 22 U.S. Companion Animal Osteoarthritis Market, for NSAIDS, 2021 - 2033 (USD Million)
  • Fig. 23 U.S. Companion Animal Osteoarthritis Market, for Others, 2021 - 2033 (USD Million)
  • Fig. 24 U.S. Companion Animal Osteoarthritis Market, for Nutritional Supplements, 2021 - 2033 (USD Million)
  • Fig. 25 U.S. Companion Animal Osteoarthritis Market, for By Animal, 2021 - 2033 (USD Million)
  • Fig. 26 U.S. Companion Animal Osteoarthritis Market, for Canine, 2021 - 2033 (USD Million)
  • Fig. 27 U.S. Companion Animal Osteoarthritis Market, for Equine, 2021 - 2033 (USD Million)
  • Fig. 28 U.S. Companion Animal Osteoarthritis Market, for Feline, 2021 - 2033 (USD Million)
  • Fig. 29 U.S. Companion Animal Osteoarthritis Market, for By Route of Administration, 2021 - 2033 (USD Million)
  • Fig. 30 U.S. Companion Animal Osteoarthritis Market, for Oral, 2021 - 2033 (USD Million)
  • Fig. 31 U.S. Companion Animal Osteoarthritis Market, for Injectable, 2021 - 2033 (USD Million)
  • Fig. 32 U.S. Companion Animal Osteoarthritis Market, for Intra-muscular, 2021 - 2033 (USD Million)
  • Fig. 33 U.S. Companion Animal Osteoarthritis Market, for Intra-articular, 2021 - 2033 (USD Million)
  • Fig. 34 U.S. Companion Animal Osteoarthritis Market, for Other Injectable, 2021 - 2033 (USD Million)
  • Fig. 35 U.S. Companion Animal Osteoarthritis Market, for Others, 2021 - 2033 (USD Million)
  • Fig. 36 U.S. Companion Animal Osteoarthritis Market, for By End Use, 2021 - 2033 (USD Million)
  • Fig. 37 U.S. Companion Animal Osteoarthritis Market, for Veterinary Hospitals/Clinics, 2021 - 2033 (USD Million)
  • Fig. 38 U.S. Companion Animal Osteoarthritis Market, for E-commerce, 2021 - 2033 (USD Million)
  • Fig. 39 U.S. Companion Animal Osteoarthritis Market, for Others, 2021 - 2033 (USD Million)